Answers are grounded in this paper and cite their sources.
Antiretroviral therapy has a very high efficacy and has substantially changed patients' quality of life, although it does need an equallyhigh adherence. The widespread use of antiretroviral therapy has significantly reduced the risk of HIV. However, at the same time it has resulted in an increase in HIV-drug resistance, which can be transmitted to newly-infected individuals, thus compromising the efficacy of combination regimens and potentially leading to the their failure. In Europe the overall prevalence of transmitted HIV-drug resistance was 8.3% in 2008-2010 and it is considered rather uncommon in non-B subtypes. In this study we report a case of drug-resistance transmission in a patient with HIV inter recombinant form infection. The transmission occurred heterosexually in a couple of immigrants without stay permit. Phylogenetic analysis was performed. Our report underlines how, even if not very high, the prevalence of HIV primary drug resistance is essential to perform the resistance test, at least of the pol gene in all new HIV diagnoses. Even in countries with high income and almost totalfree diagnosis and treatment, some patient settings are at risk of developing drug-resistant strains. More studies are needed for the proper evaluation of transmitted HIVDR in non-B subtypes of HIV.
No takes yet. Share an insight, caveat, or question.
Gaetano Brindicci (2018) studied this question.
Synapse has enriched 9 related papers. Consider them for comparative context: